EMA Authorised: Herzuma (trastuzumab) — Celltrion Healthcare Hungary Kft.

View source ↗

Summary

The EMA authorised Herzuma, a trastuzumab biosimilar from Celltrion Healthcare Hungary Kft, for stomach cancer and breast cancer in the EU.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Stomach Cancer

Drugs mentioned

• HERZUMA (TRASTUZUMAB)

Snippet

Status: Authorised. Therapeutic area: Stomach Neoplasms;Breast Neoplasms. MAH: Celltrion Healthcare Hungary Kft.. Decision date: 26/01/2026